According to the Zhitong Finance App, Weilizhibo-B (09887) announced that six of its latest research results were selected for the 2026 European Society of Medical Oncology (ESMO) Annual Meeting. Of the six studies selected this time, two were selected for the highest standard oral presentation (preferred oral report), and four were presented on posters, covering treatment areas such as extrapulmonary neuroendocrine cancer (EP-NEC), biliary tract cancer (BTC), and recurrent/refractory multiple myeloma (RRMM). Additionally, the company has been awarded the Latest Breakthrough Summary (LBA) status and will submit the full LBA in September 2026.
The ESMO Annual Conference is one of the most influential academic events in the field of oncology in the world. The conference will be held in Madrid, Spain from October 23 to 27, 2026. The preferred oral report is the highest standard oral report at the ESMO annual conference. It is specially designed for research with the most significant clinical significance and scientific innovation. LBA is a specific category for the latest clinical research developments that are seen as groundbreaking and have the potential to change clinical practice. The company's multiple studies were selected at the same time, reflecting the international academic community's recognition of the company's clinical data quality and pipeline value, and highlighting the company's continuous innovation ability and strong pipeline development momentum in the field of tumor immunotherapy. The full data of the selected studies will be published online in the ESMO abstract and published during the conference.
The company also previously announced that the study of Vilisin™ for the treatment of first-line non-small cell lung cancer (1LNSCLC) was selected for an oral report at the World Lung Cancer Conference (WCLC) to be held in September 2026. The full abstract is expected to be published on the WCLC official website on August 19, 2026.